Edition:
India

People: Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

82.09USD
25 Jun 2019
Change (% chg)

-- (--)
Prev Close
$82.09
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
79,378
52-wk High
$127.74
52-wk Low
$64.25

Adda, Nathalie 

Dr. Nathalie Adda M.D. is Senior Vice President and Chief Medical Officer of the Company, since June 2015. Prior to joining Enanta, Dr. Adda was Chief Medical Officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene SA, where she led the Oncology and Infectious Disease programs since 2012. From 2006 to 2012, she was Senior Medical Director and the medical lead for the Incivek® (telaprevir) Clinical Program at Vertex Pharmaceuticals, Inc. Earlier in her career, Dr. Adda held medical and research positions at Gilead, Triangle Pharmaceuticals and Boehringer Ingelheim, where she worked on programs for infectious diseases such as human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Dr. Adda is a graduate of the University of Paris, where she received a Doctorate in Medicine, as well as a Master’s Degree in Biostatistics, and where she did post- graduate work in infectious diseases.

Basic Compensation

Total Annual Compensation, USD 421,425
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,092,650
Fiscal Year Total, USD 1,514,080

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 17,730 1,058,510.00
Name Fiscal Year Total

Bruce Carter

394,190

Jay Luly

4,508,740

Paul Mellett

1,421,280

Yat Sun Or

1,524,000

Nathaniel Gardiner

1,376,110

Nathalie Adda

1,514,080
As Of  30 Sep 2018